- Market Capitalization, $K 12,934
- Shares Outstanding, K 3,117
- Annual Sales, $ 0 K
- Annual Income, $ -39,280 K
- 60-Month Beta -0.55
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 0.35
|Period||Period Low||Period High||Performance|
| || |
+0.18 (+4.48%)since 11/06/23
| || |
+0.68 (+19.40%)since 09/06/23
| || |
+1.90 (+82.85%)since 12/06/22
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of...
Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical...
Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed...
Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...
Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma,...